DCM
EBS icon

Delpha Capital Management’s Emergent Biosolutions EBS Stock Holding History

Delpha Capital Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-660
Closed -$31K – 426
2017
Q4 		$31K Buy
+660
New +$27.8K 0.03% 540

Other funds holding EBS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.79B AUM 33.56% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Delpha Capital Management's EBS Position: Q1 2018 in Review

Delpha Capital Management sold out of Emergent Biosolutions (EBS) in Q1 2018, closing a stake of 660 shares — an estimated $31K sold.

Delpha Capital Management first reported a position in EBS in Q4 2017 and held it in 1 quarter. The position peaked at $31K in Q4 2017. 272 funds tracked by Wall St. Rank hold EBS as of Q1 2018.

  • Delpha Capital Management reported no remaining Emergent Biosolutions position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 660 Emergent Biosolutions shares in Q1 2018, an estimated $31K.
  • Delpha Capital Management first reported a position in Emergent Biosolutions in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's Emergent Biosolutions position peaked at $31K in Q4 2017.
  • 272 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.